Interleukin-28A enhances autoimmune disease in a retinal autoimmunity model.Interleukin-28A (IL-28A), a member of type III interferons (IFN-λs), promotes antiviral, antitumor and immune responses.  In this study, we examined the effect of IL-28A on retinal antigen-induced experimental autoimmune uveoretinitis (EAU), a mouse model of human T-cell-mediated autoimmune eye disease.  We found that administration of IL-28A enhanced EAU scores and autoimmune response parameters including delayed-type hypersensitivity (DTH), Ag-specific T cell proliferation and the production of Ag-specific IL-17 and IFN-γ in the priming phase.  The effect of IL-28A was abrogated by administration of a neutralizing antibody against IL-28A.  Our results suggest that IL-28A is capable of exacerbating a T-cell-mediated autoimmune disease.  Thus, targeting IL-28A may provide a new therapeutic approach to T cell-mediated autoimmune diseases such as uveitis.
IL-28A
Interleukin-28A enhances autoimmune disease in a retinal autoimmunity model.Interleukin-28A (IL-28A), a member of type III interferons (IFN-λs), promotes antiviral, antitumor and immune responses.  In this study, we examined the effect of IL-28A on retinal antigen-induced experimental autoimmune uveoretinitis (EAU), a mouse model of human T-cell-mediated autoimmune eye disease.  We found that administration of IL-28A enhanced EAU scores and autoimmune response parameters including delayed-type hypersensitivity (DTH), Ag-specific T cell proliferation and the production of Ag-specific IL-17 and IFN-γ in the priming phase.  The effect of IL-28A was abrogated by administration of a neutralizing antibody against IL-28A.  Our results suggest that IL-28A is capable of exacerbating a T-cell-mediated autoimmune disease.  Thus, targeting IL-28A may provide a new therapeutic approach to T cell-mediated autoimmune diseases such as uveitis.
IL-28A
Interleukin-28A enhances autoimmune disease in a retinal autoimmunity model.Interleukin-28A (IL-28A), a member of type III interferons (IFN-λs), promotes antiviral, antitumor and immune responses.  In this study, we examined the effect of IL-28A on retinal antigen-induced experimental autoimmune uveoretinitis (EAU), a mouse model of human T-cell-mediated autoimmune eye disease.  We found that administration of IL-28A enhanced EAU scores and autoimmune response parameters including delayed-type hypersensitivity (DTH), Ag-specific T cell proliferation and the production of Ag-specific IL-17 and IFN-γ in the priming phase.  The effect of IL-28A was abrogated by administration of a neutralizing antibody against IL-28A.  Our results suggest that IL-28A is capable of exacerbating a T-cell-mediated autoimmune disease.  Thus, targeting IL-28A may provide a new therapeutic approach to T cell-mediated autoimmune diseases such as uveitis.
IL-28A
Interleukin-28A enhances autoimmune disease in a retinal autoimmunity model.Interleukin-28A (IL-28A), a member of type III interferons (IFN-λs), promotes antiviral, antitumor and immune responses.  In this study, we examined the effect of IL-28A on retinal antigen-induced experimental autoimmune uveoretinitis (EAU), a mouse model of human T-cell-mediated autoimmune eye disease.  We found that administration of IL-28A enhanced EAU scores and autoimmune response parameters including delayed-type hypersensitivity (DTH), Ag-specific T cell proliferation and the production of Ag-specific IL-17 and IFN-γ in the priming phase.  The effect of IL-28A was abrogated by administration of a neutralizing antibody against IL-28A.  Our results suggest that IL-28A is capable of exacerbating a T-cell-mediated autoimmune disease.  Thus, targeting IL-28A may provide a new therapeutic approach to T cell-mediated autoimmune diseases such as uveitis.
IL-28A
The effect of IL-28A was abrogated by administration of a neutralizing antibody against IL-28A. 
neutralizing antibody against IL-28A
Interleukin-28A enhances autoimmune disease in a retinal autoimmunity model.Interleukin-28A (IL-28A), a member of type III interferons (IFN-λs), promotes antiviral, antitumor and immune responses.  In this study, we examined the effect of IL-28A on retinal antigen-induced experimental autoimmune uveoretinitis (EAU), a mouse model of human T-cell-mediated autoimmune eye disease.  We found that administration of IL-28A enhanced EAU scores and autoimmune response parameters including delayed-type hypersensitivity (DTH), Ag-specific T cell proliferation and the production of Ag-specific IL-17 and IFN-γ in the priming phase.  The effect of IL-28A was abrogated by administration of a neutralizing antibody against IL-28A.  Our results suggest that IL-28A is capable of exacerbating a T-cell-mediated autoimmune disease.  Thus, targeting IL-28A may provide a new therapeutic approach to T cell-mediated autoimmune diseases such as uveitis.
IL-28A